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Background: Experiments with tumor necrosis factor  (TNF) in rodents have shown that a high
dose can lead to hemorrhagic necrosis in tumors. Endothelial monocyte-activating polypeptide II
(EMAP-II) is a novel tumor-derived cytokine, and its expression increases the TNF-1 receptor on
tumor endothelium, enhances the induction of tissue factor on tumor endothelial cells, and has an
antiangiogenic effect. It has recently been shown that in vivo sensitivity of tumor vasculature to TNF
is determined by tumor production of EMAP-II.
Methods: We measured the level of EMAP-II in a TNF-resistant soft tissue sarcoma. We
subsequently stabile-transfected this cell line with a retroviral construct containing the EMAP gene.
In an extremity perfusion model in tumor-bearing rats, we measured response rates to TNF therapy.
Results: Functional EMAP-II production was increased after this transfection. Immunostaining of
paraffin-embedded tumor tissue sections in rats showed an overexpression of human EMAP-II.
Results of the TNF perfusions in rats suggest that this tumor is more sensitive to TNF therapy.
Conclusions: EMAP-II is produced in various levels. One can increase the sensitivity of tumor
for TNF therapy in vivo by upregulating the EMAP-II production. This result leaves an opportunity
for enhanced TNF response of tumors in future settings.
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Studies of the antitumor activity of systemically admin-
istered tumor necrosis factor (TNF) in humans have been
hampered by severe dose-limiting toxicity at relatively low
doses of the cytokine which are insufficient for an antitumor
response.1 This situation changed when TNF was applied in
the isolated limb perfusion (ILP) setting. The efficacy of the
application of TNF in combination with cytostatic agents in
ILP for the treatment of patients with in-transit melanoma
metastases or locally advanced soft tissue sarcomas has
now been well established.1–3 This treatment can be used as
a limb-sparing neoadjuvant therapy when it is followed by
local excision of residual tumor. TNF became a registered
cancer drug in Europe on the basis of results obtained in
multicenter studies in which clinical response rates of 75%
and limb salvage rates of 71% were observed in 196 pa-
tients who had been classified as having unresectable tu-
mors that could have been managed only by amputation.
Approval by the European Agency for the Evaluation of
Medicinal Products was given for the use of TNF in the
setting of an ILP for locally advanced extremity grade II to
III soft tissue sarcomas.4 However, 25% of all patients
remain in whom we cannot achieve a sufficient antitumor
effect for limb preservation. The answer as to why this
group of patients is not responding is not known.
There is evidence that the mechanism of action of TNF
is not directly on tumor cells, but that it acts indirectly by
destruction of tumor-associated endothelium.5 This destruc-
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tion may eventually lead to the death of tumor cells when
TNF is used in combination with an antitumor drug. The
antitumor effects after TNF-containing ILPs can be ex-
tremely rapid, indicating that the TNF-mediated collapse of
the tumor vascular bed may play an essential role in the
antitumor mechanism. The selective destructive effects of
TNF ILP on tumor-associated vessels have been illustrated
in the clinic by means of pre- and postperfusion angiogra-
phy.1 Severe hemorrhagic necrosis accompanied with vas-
cular destruction was observed after ILP with TNF in
combination with melphalan.
Our laboratory has developed ILP models with different
tumors in rats to study prerequisites for improving efficacy
and to study mechanisms of synergy.6,7 These models
mimic the clinical setting closely with respect to response
rate and histopathology. The crucial observation has been
that TNF selectively and highly significantly enhances the
uptake of melphalan and doxorubicin in the tumors.6
Endothelial monocyte-activating polypeptide II (EMAP-
II) is a tumor-derived cytokine with proinflammatory prop-
erties. It induces procoagulant activity on the surface of
endothelial cells and monocytes/macrophages in vitro, as
well as upregulation of E- and P-selectin expression and the
ability to upregulate TNF receptor-1 expression on tumor
vasculature. Furthermore, EMAP-II induces apoptosis and
has antiangiogenic effects.1 These data led us to hypothe-
size that EMAP-II could be of additional benefit in the TNF
perfusion circuit. Wu et al.8 defined a way to upregulate
EMAP-II production by means of retroviral transfection in
a melanoma cell line. We used this method of transfection
on a TNF-resistant soft tissue sarcoma. We describe here
the application of the sensitizing gene therapy and subse-
quent regional TNF treatment and its effects on in vivo
tumor growth. Because EMAP-II can have additional ben-
efits in long-term anticancer treatment regarding its antian-
giogenic effect (e.g., to prevent outgrowth of neovascula-
ture and metastases) and is toxic when injected
systemically, a long-lasting and local production of
EMAP-II in a tumor should be favorable. This can be
maintained after retroviral transfection and subsequent up-
regulation of the protein synthesis by tumor cells. It was our
goal to identify factors of TNF resistance or sensitivity and
the potential role of EMAP-II in this.
MATERIALS AND METHODS
Animals
Inbred male Brown Norway (BN) rats, weighing 200 to
300 g, were obtained from Harlan-CPB (Austerlitz, The
Netherlands). All animals were kept at standard laboratory
conditions and were fed a standard laboratory diet (Hope
Farms, Woerden, The Netherlands). The experimental pro-
tocols adhered to the rules laid down in the Dutch Animal
Experimentation Act (1977) and the published Guidelines
on the Protection of Experimental Animals by the council of
the European Community (1986). All animal studies were
performed in accordance with protocols approved by the
Animal Care Committee of the Erasmus University of Rot-
terdam, The Netherlands.
Tumor Cell Lines
BN-175 is a nonimmunogenic, rapidly growing soft
tissue sarcoma syngeneic in BN rats, with a tumor
doubling time of approximately 2 to 3 days. This
tumor was implanted into the flank of donor rats and
passaged serially. For this study we used small tumor
fragments (1 mm2) that were subcutaneously im-
planted into the right hind limb just above the ankle.
All surgical interventions were performed at a tumor
diameter of 5 to 10 mm, at least 7 days after implan-
tation. Rats were killed if tumor diameter exceeded 25
mm. The human umbilical vein endothelial cells
(HUVECs) used were obtained from BioWhittaker
Europe (Verviers, Belgium) and consisted of pooled
cells by multiple donors.
Drugs
Recombinant human TNF- (4.9–5.8  107 U/mg),
recombinant human EMAP-II (hEMAP-II; 3.85 g/mL),
and antibodies directed to hEMAP-II were provided as a
kind gift by Dr. G. Adolf (Boehringer Ingelheim GmbH,
Vienna, Germany).
Transfection of BN-175 Tumor Cells With the
EMAP-II Gene
Viral supernatant from the Gibbon Ape ecotropic
packaging cell line PG-WU was used to transfect the
BN-175 tumor cell line. Tumors were grown in six-well
plates to approximately 40% confluence. The viral su-
pernatant was then collected and filtered across a .45-m
low–protein-binding membrane (Corning Costar, Cam-
bridge, MA), and polybrene (Sequa Brene; Sigma, St.
Louis, MO) was added at a concentration of 1 l/mL of
supernatant. Tumor cells were washed twice with phos-
phate-buffered saline (PBS) and incubated for 6 hours on
3 subsequent days in an incubator at 37°C and 5% CO2.
In between incubation with viral supernatant, cells were
given normal medium to recover. After 5 to 7 days, the
transfected tumor cells (named BN-E) were placed into
75-cm2 flasks and expanded under neomycin selection at
800 g/mL.
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Detection of Incorporation of hEMAP in Genomic
DNA of Rat Tumor Cells by PCR
Transfected tumor cells growing in 800 g/mL of
neomycin were trypsinated and pelleted. DNA was ex-
tracted with the QIamp DNA minikit (Qiagen Inc., Va-
lencia, CA) and amplified by PCR by using primers
specific for both a part of the EMAP insert and the
downstream retroviral internal ribosome entry site re-
gion. For EMAP, the following primers were used: 5'-
AATCGGATGGTGATTTTACTTTGTA-3' at both
times as the forward primer and backward; 5'-CATTT-
TATTTGATTCCACTGTTGC-3' with a PCR product of
333 base pairs (bp) for the EMAP part; and backward for
the internal ribosome entry site and EMAP 5'-GAAT-
GCTCGTCAAGAAGACAG-3', providing a 577-bp
PCR product. PCR amplification was performed under
the following conditions: 5 minutes at 95°C, 35 cycles
(94°C for 45 seconds, 55°C for 45 seconds, and 72°C for
60 seconds); and 7 minutes at 72°C, soak at 4°C. Am-
plified PCR products were subjected to gel electrophore-
sis on a 1% agarose gel containing ethidium bromide.
Western Blot Analysis of Transfected Tumor Cells
for EMAP
After transfection of the tumor cells, cells were col-
lected, washed, and centrifuged. Cell pellets were lysed
at 4°C in a buffer containing 50 mM TrisCl (pH 8.0), 150
mM NaCl, .02% Na-azide, .1% sodium dodecyl sulfate,
1 g/mL of aprotinin, 5% Na-deoxycholate, 1% Nonidet
P-40 (Sigma-Aldrich, Zwijndrecht, The Netherlands),
deoxyribonuclease I 10 ng/mL, and 100 g/mL of phe-
nylmethyl sulfonyl fluoride for 10 minutes. Samples
were vortexed, and debris was pelleted by centrifugation
at 15,000  g for 10 minutes. Supernatant protein con-
tent was determined by BCA protein assay (Pierce
Chemical Co., Rockford, IL), and a final loading con-
centration of 120 g per sample was used. Lysates were
mixed with Laemmli buffer containing 5% -mercapto-
ethanol, boiled for 5 minutes, and electrophoresed on a
15% acrylamide gel by using sodium dodecyl sulfate
polyacrylamide gel electrophoresis. The membranes
were subsequently blocked for nonspecific binding over-
night at 4°C with PBS/5% nonfat dry milk/.05% Tween
and incubated for 2 hours with EMAP-II polyclonal
rabbit antiserum (diluted 1/2000 in PBS/5% nonfat dry
milk/.05% Tween). After washing thoroughly, the mem-
branes were incubated for 1 hour with biotinylated goat
anti-rabbit immunoglobulin G antiserum (diluted 1/3000
in PBS/5% nonfat dry milk/.05% Tween). Membranes
were again washed and incubated with alkaline phos-
phatase–labeled streptavidin and developed with en-
hanced chemiluminescence by adding bromo-cloro-
indolyl-phosphate/nitro-blue-tetrazolium.
Coagulation Assay
Conditioned medium from wild-type BN-175 and
BN-E tumor cell lines was tested for procoagulant activ-
ity by using a two-stage coagulation assay. HUVECs
were grown to ~80% confluence in six-well multiwell
tissue culture plates in complete endothelial growth me-
dia (Cambrex Bio Science, Baltimore, MD). Cells were
washed twice with sterile PBS. Tumor-conditioned me-
dium was produced by growing ~5 106 tumor cells per
75-cm2 tissue culture flask in 15 mL of serum-free me-
dium. After 24 hours, conditioned medium was collected
and vacuum-filtered across a .45-m membrane to re-
move cellular debris and was used directly. HUVECs
were treated at a concentration of 1 mL of conditioned
medium per well. Normal medium was used as a nega-
tive control, and TNF- at a concentration of 1 g/mL of
medium was used as a positive control. The samples
were incubated for 6 hours at 37°C in a 5% CO2 incu-
bator and assayed for procoagulant activity. Medium was
removed from the treated HUVECs, and cells were
washed with Ca/Mg-free PBS. After 10 minutes of in-
cubation with 1 mL of 25 mM Tris/ethylenediaminetet-
raacetic acid (pH 7.4) per well, cells could be gently
removed from the wells and subsequently collected and
centrifuged at 14,000  g for 10 minutes at room tem-
perature. Supernatant was carefully removed, and the
resultant cell pellet was resuspended in a 100-l assay
buffer (buffer: 250 l of 1 M Tris; 300 l of 5 M NaCl;
10 mg of .1% bovine serum albumin; distilled H2O to 10
mL) and shortly vortexed. Cell pellet was added to 100
l of human citrated plasma (Biopool, Venture, CA),
mixed well, and incubated at 37°C for 3 minutes in a
clinical fibrometer. The coagulation reaction was cata-
lyzed by adding 100 l of 30 mM CaCl2 (Sigma), and
clotting time was measured. Standard curves were gen-
erated by using lipidated recombinant human tissue fac-
tor (American Diagnostica, Greenwich, CT).
Immunohistochemical Staining of hEMAP in Rat
Tumor Tissue
Tumor was induced by subcutaneous injection of ~2
106 BN or BN-E tumor cells in the flank region of
syngeneic BN rats. When the tumor reached 10 mm in
diameter, it was resected from the animal, immediately
fixated in 4% formalin, and embedded in paraffin. As-
sessment of tumor morphology was performed on 5- to
8-m hematoxylin and eosin–stained sections. Before
staining for EMAP-II, sections were dewaxed with xy-
lene and rehydrated by passing through a graded series of
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alcohol (100%–70%) followed by PBS. Sections were
microwaved two times for 5 minutes in .01 M citrate
buffer (2.10 g/L of citric acid and 1 g/L of sodium
hydroxide) to enhance immunoreactivity. All incubations
were performed in a humidified chamber at room tem-
perature. Sections were incubated in 5% normal goat
serum for 30 minutes to block nonspecific binding of
antibodies. Sections were rinsed with PBS/Tween, and
rabbit polyclonal antibody against hEMAP-II was added
at a 1/100 dilution. Polyclonal rabbit immunoglobulin G
(Santa Cruz Biotechnology, Santa Cruz, CA) was used as
a negative control. Sections were incubated for 1 hour,
washed three times with PBS, and subsequently incu-
bated with goat anti-rabbit secondary antibody conju-
gated to peroxidase for 1 hour. After washing three times
in PBS, slides were incubated with the avidin-biotin
complex reagent, followed by diaminobenzidine sub-
strate. Thereafter the slides were rinsed with distilled
water and counterstained with hematoxylin. Finally,
slides were dehydrated with graded alcohol and xylene
and covered with DPX. Sections were examined with a
Leica (Wetzlar, Germany) DM-RXA microscope, and
images were made by using a Sony (Tokyo, Japan)
DXC950 digital camera.
ILP Model
The perfusion technique was performed as described
previously.6,7,9 In our laboratory, Manusama et al.7 mod-
ified the technique of ILP in rats, originally described by
Benckhuijsen et al.10 In this model, by using the BN-175
soft tissue sarcoma, it was shown that only when TNF
was combined with melphalan or doxorubicin could a
tumor response be reached. In comparison to the clinical
setting, our rat model demonstrated partial or complete
regression of the tumor in approximately 75% of rats
receiving an ILP with melphalan plus TNF. We used the
BN-175 soft tissue sarcoma to set up an experimental
environment where we could improve the response rate
to TNF.
Briefly, small fragments (3–5 mm) of tumor were
implanted subcutaneously into the right hind limb of the
rat. Approximately 7 to 8 days after implantation, tumors
reached an average diameter of 8 to 12 mm, and then
treatment was started. Animals were anesthetized with
Hypnorm (Janssen Pharmaceutica, Tilburg, The Nether-
lands) and ketamine (Apharmo BV, Arnhem, The Neth-
erlands). Heparin (50 IU) was injected intravenously to
prevent coagulation. To keep the rat’s hind limb at a
constant temperature, a warm-water mattress was ap-
plied. Temperature was measured with a temperature
probe on the skin covering the tumor and was maintained
between 38°C and 39°C. The femoral artery and vein
were cannulated with silastic tubing (.012-inch inner
diameter, .025-inch outer diameter; and .025-inch inner
diameter, .047 inch outer diameter, respectively; Dow
Corning, Midland, MI). Collaterals were occluded by a
groin tourniquet, and the time of isolation started when
the tourniquet was tightened. An oxygenation reservoir
and a roller pump were included into the circuit. The
perfusion solution consisted of 5 mL of Hemaccel (Be-
hring Pharma, Amsterdam, The Netherlands) in the sham
perfusions, and TNF (50 g) was added to the oxygen-
ation reservoir as a bolus in the treatment group. A roller
pump (type 505 U; Watson Marlow, Falmouth, UK)
recirculated the perfusate at a flow rate of 2.4 mL/min. A
washout with 5 mL of oxygenated Hemaccel was per-
formed at the end of the perfusion. After the perfusion,
the cannulas were removed, and the femoral vessels of
the perfused limb were ligated. The extensive collateral
circulation was capable of restoring the blood supply of
the perfused leg.
The perfusion with the wild-type tumor took place 16
hours after intravenous injection with recombinant
EMAP-II. In these experiments, 50 g of recombinant
EMAP-II, dissolved in 200 l of PBS, was injected
intravenously. Rats were closely monitored afterward,
and moderate but reversible toxicity was observed after
IV administration. Subsequent tumor growth was re-
corded daily by caliper measurement. Tumor volume
was calculated as .4  (A2  B), where B represents the
longest diameter and A the diameter perpendicular to B.
RESULTS
Transfection of the EMAP-II Gene
Rat soft tissue sarcoma cells were transfected in vitro
with retroviral particles containing the P. Wu construct
(BN-E) and seemed resistant to continuous exposure
with 800 g/mL of neomycin, demonstrating effective
transfection with the construct (data not shown). After 2
weeks of growing in selection media, genomic DNA was
extracted from the transfected tumor cell lines. PCR
analysis of expression of the EMAP-II gene proved pos-
itive for the BN-E cell line (data not shown). Western
blot analysis of 120 g of protein of cell lysate of
wild-type and transfected tumor cells, compared with
100 ng of recombinant EMAP-II, demonstrated a band
corresponding to the size of the human precursor EMAP-
II, ~34 kDa (Fig. 1). We show only the results with
normally growing tumor cells. In our ongoing experi-
ments, we would like to demonstrate the generation of
active EMAP-II (~22 kDa) that was used as a control in
these experiments, and we would like to show interme-
diate cleavage products by inducing apoptosis in the
815EMAP-II IMPROVES TUMOR RESPONSE TO TNF
Ann Surg Oncol, Vol. 9, No. 8, 2002
tumor cells. However, this expression seems to be very
unstable and transient and shows tremendous variation.
Coagulation Assay
We wanted to test whether the EMAP-II–transfected
cell line, BN-E, produced functional protein. We used a
functional bioassay of EMAP-II activity based on the
induction of tissue factor expression on human endothe-
lial cells. HUVECs were treated with conditioned me-
dium of transfected tumor cells. As shown in Fig. 2, a
6-hour exposure of HUVECs to medium conditioned by
tumor transfected with EMAP-II (BN-E) induced a 20%
increase in the production of tissue factor by these cells,
as compared with treatment with conditioned medium
from wild-type BN or medium alone.
Immunohistochemical Staining of hEMAP in Rat
Tumor Tissue
The tumor model used for our in vivo studies was gen-
erated by subcutaneous injection of 2  106 transfected
tumor cells in the hind limb of a syngeneic BN rat. Tumors
were grown to an average diameter of 8–12 mm, and we
observed a growth rate corresponding to a wild-type tumor.
As shown in Fig. 3, cells stained positive for EMAP-II as
compared with controls. On the hematoxylin and eosin
staining (Fig. 4), the morphology of the transfected tumor
was altered with a tendency to more apoptotic cells. This,
however, was not reflected in the growth rate of the BN-E.
We regard this as apoptosis being induced by the increased
EMAP-II production of this tumor.
ILP in Rats With Transfected Tumor
In Figure 5, the results of TNF ILP in rats bearing the
BN-E tumor compared with the wild-type tumor are
FIG. 1. Western blots were performed
with 120 g of protein isolated from cell
lysate from transfected cell lines. PS, pro-
tein scale; C, control recombinant human
endothelial monocyte-activating polypep-
tide II (100 ng); BN, wild-type tumor;
BN-E, transfected tumor.
FIG. 2. Tissue factor assay. Lane 1: Positive control; medium of cells
treated with 1 g of tumor necrosis factor . Lane 2: Medium of
untreated cells. Lane 3: Wild-type tumor medium (BN). Lane 4:
Transfected tumor medium (BN-E). Conc TF, concentration of recom-
binant human tissue factor (American Diagnostica, Greenwich, CT).
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shown. Perfusion with Hemaccel alone resulted in pro-
gressive disease in all animals. Although ILP with TNF
resulted in a slight inhibition of tumor growth of the
wild-type BN tumor compared with the sham control,
there was no significant difference in tumor response. As
can be seen in this graph, the EMAP-II–transfected tu-
mor BN-E responded significantly better to ILP with 50
g of TNF. We saw macroscopically a more profound
necrosis in the BN-E tumor that led to a significantly
slower outgrowth of tumor after the perfusion. Even in
animals with transfected tumors, a small rim of viable
tumor cells survived. However, as can be seen at day 9,
the overall observed response rate still implied a decline
in tumor dimension, whereas profound recurrent tumor
growth was demonstrated in all animals from day 11.
ILP in Rats Preceded by Recombinant EMAP-II
Injection
A total of 50 g of recombinant EMAP-II was in-
jected intravenously into rats 16 hours before TNF per-
fusion. Rats showed a moderate toxic response immedi-
ately after injection; nevertheless, this was reversible
within 4 hours. Figure 6 shows the tumor volume of
animals treated with TNF perfusion after pretreatment
with recombinant EMAP-II. Sham perfusions after
EMAP-II injection were also performed. From the sec-
ond day, a significant difference in tumor volume was
observed in TNF-treated animals bearing the BN-E ver-
sus wild-type tumor. Tumors treated with sham perfusion
or TNF ILP alone continued to grow; the recombinant
EMAP-II pretreated animals showed a delay in tumor
growth after TNF ILP. This difference was observed
until the ninth day, when both groups started to develop
the same growth rate. Both wild-type and BN-E tumors
FIG. 3. Immunohistochemical staining with human endothelial
monocyte-activating polypeptide II (hEMAP-II) (100). (A) Nontrans-
fected tumor. (B) Marked upregulation of the intracellular present
hEMAP-II.
FIG. 4. Hematoxylin and eosin–stained tumor sections (100). (A)
Normal morphology of wild-type viable tumor cells. (B) Transfected
tumor is shown with an aspect of more profound necrosis, disruption of
cell structure, and smaller cells.
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showed the same growth rate in the presence of system-
ically administered recombinant EMAP-II alone.
DISCUSSION
The results presented in this study show that transfec-
tion with EMAP-II of the TNF-resistant tumor BN-175
will render this tumor TNF sensitive and responsive to
ILP treatment with TNF. This approach could enhance
efficacy in the clinical setting, where 25% of patients
with locally advanced limb-threatening extremity soft
tissue sarcoma do not respond to TNF plus chemother-
apy in the ILP setting for limb salvage to be achieved.
By introducing isolated perfusion as a mode to apply
TNF in patients, we have been able to achieve effective
concentrations of TNF in the tumor region. Antitumor ef-
fects after TNF-containing ILPs can be extremely rapid.
This indicates that also in humans the TNF-mediated col-
lapse of the tumor vascular bed plays an essential role in the
antitumor mechanism, as has been illustrated in publica-
tions on clinical studies by pre- and postperfusion angiog-
raphy.11 Moreover, in studies in sarcoma patients with
magnetic resonance spectrometry, we have clearly shown
that the metabolic shutdown of the tumor is virtually com-
plete within 16 hours after the perfusion, confirming the
likelihood of TNF mediating its most important effects on
the vasculature of the tumor.11 At the histopathologic level,
these intravascular effects—such as thrombocyte aggrega-
tion, erythrostasis, and endothelial and vascular destruc-
tion—have been described for the early-stage changes after
ILP, which may closely resemble observations made in
experimental tumor systems.11
Because TNF is known to act on the tumor endothe-
lium, a range of cytotoxic agents have been used in
combination to have an additional antitumor effect. After
the initial destruction of tumor vessels, these agents can
exert their toxic effect on the tumor cells.
We introduce here an approach based on a different
mechanism to improve the effect of TNF therapy. After the
observation that varying tumors respond in a distinct man-
ner to TNF, a cytokine that contributes to this response was
isolated. This cytokine, EMAP-II, is produced by tumors
and influences the formation of neovasculature in a number
of ways, one of them being the upregulation of TNF recep-
tor-1 on tumor-associated endothelial cells. This is an im-
portant finding regarding the use of TNF as anticancer
therapy.
Therefore, we investigated whether we could enhance
the TNF sensitivity of a nonresponding rat sarcoma in
vivo by transfecting the tumor with EMAP-II, to increase
its endogenous EMAP-II content. EMAP-II is a tumor-
derived cytokine with proinflammatory properties, in-
ducing procoagulant activity on the surface of endothe-
lial cells and monocytes/macrophages in vitro, as well as
upregulation of E- and P-selectin expression and the
ability to upregulate TNF receptor-1 expression on tumor
vasculature.12 The distribution of EMAP-II protein is
relatively restricted and is usually associated with tissues
that display high turnover and high levels of protein
synthesis, e.g., tumor tissue.13 It was first isolated from
the conditioned medium of the murine methylchol-
antrene A-induced fibrosarcoma. This tumor responds
well to TNF therapy, and investigators found that in the
supernatant of this tumor, the cytokine EMAP-II was
excreted. Studies have shown that EMAP-II is capable of
sensitizing resistant tumors to the antitumor effects of
TNF.14,15 In response to EMAP-II exposure, endothelial
cells are activated, and the expression of TNF receptor-1
FIG. 5. Growth curves of wild-type tumor after isolated limb perfu-
sion (ILP) with sham (e) (n  5) and tumor necrosis factor (TNF) (Œ)
(n  7) and of transfected tumor after ILP with sham () (n  7) and
TNF (‚) (n  5). FIG. 6. Results of isolated limb perfusion (ILP) in wild-type (BN)tumor. Control tumor (□), n  6; sham perfusion, () n  5; tumor
necrosis factor (TNF) (Œ), n  7; endothelial monocyte-activating
polypeptide II (EMAP-II) followed by sham perfusion (); and ILP
with EMAP-II plus TNF (), n  6.
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is upregulated, an effect that is known to take place
between 16 and 24 hours after exposure to EMAP-II.15 It
led us to hypothesize that EMAP-II could be of addi-
tional benefit in the TNF perfusion circuit. This enabled
us to create a more sensitive tumor to TNF therapy,
without the toxic side effects of systemic EMAP-II ap-
plication. In our next experiments, we injected recombi-
nant hEMAP into rats that were 16 hours later subjected
to an ILP system with TNF. With a dose of 50 g of
recombinant EMAP per rat combined with 50 g of
TNF, we saw a significant decrease of growth of the
tumors, with an immediate, although moderate and re-
versible, toxic reaction to the injected EMAP-II. These
results were comparable with the effect seen in the trans-
fected tumor and suggest that this effect is mediated by
EMAP-II, rather than being an effect created by trans-
fection of the tumor or an effect seen because of varying
levels of EMAP-II receptors.
ILP is an interesting method for new treatment modali-
ties, such as adenoviral vector–mediated gene therapy.16,17
In our laboratory, we have shown that ILP is the best and
most selective method for effective homogeneous transvas-
cular local gene delivery by using adenoviral vectors. Ex-
periments in our soft tissue sarcoma and osteosarcoma ILP
models have clearly shown this by making use of lucif-
erase-marker gene and LacZ gene methodology.18 More-
over, we have shown that ILP with adenoviral vector gene
delivery of the cytokine interleukin-3 is the only method in
these tumor models to achieve good tumor responses, in
contrast to the failure of other methods, such as intravenous
administration, intra-arterial administration, or intratumoral
administration.17 It demonstrates that ILP is a valuable
method to treat advanced limb tumors and to develop new
treatment modalities.
The possibility of manipulating the sensitivity for TNF
in a tumor in vivo also leaves a window for systemic
application of TNF in future settings. If noninvasive
vectors can increase tumor sensitivity in a way that the
TNF dose can be decreased, we might be able to save
patients in the future by the invasive perfusion procedure
and be able to administer TNF systemically.
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